Viking Therapeutics, Inc. (VKTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
VKTX Stock Price Chart Interactive Chart >
VKTX Price/Volume Stats
|Current price||$4.01||52-week high||$5.65|
|Prev. close||$4.09||52-week low||$2.02|
|Day high||$4.07||Avg. volume||969,763|
|50-day MA||$3.60||Dividend yield||N/A|
|200-day MA||$3.14||Market Cap||307.52M|
Viking Therapeutics, Inc. (VKTX) Company Bio
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.
Most Popular Stories View All
VKTX Latest News Stream
|Loading, please wait...|
VKTX Latest Social Stream
View Full VKTX Social Stream
Latest VKTX News From Around the Web
Below are the latest news stories about VIKING THERAPEUTICS INC that investors may wish to consider to help them evaluate VKTX as an investment opportunity.
Biotech stocks, on balance, had a year to forget in 2022. An unsavory mix of profit-taking, clinical setbacks, a stricter Food and Drug Administration (FDA), geopolitcal unrest, rising interest rates, and good old fashioned risk aversion sent key indicators like the SPDR S&P Biotech ETF spiraling downward this year. Hammering this point home, the SPDR S&P Biotech ETF plummeted by a staggering 53% -- from its prior three-year high -- through the first 11 months of 2022.
Insiders were net buyers of Viking Therapeutics, Inc.'s ( NASDAQ:VKTX ) stock during the past year. That is, insiders...
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the Stifel 2022 Healthcare Conference. The conference will take place November 15-16, 2022, in New York City.
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viking Therapeutics (VKTX – Research Report) and Sanofi (SNYNF – Research Report) with bullish sentiments. Viking Therapeutics (VKTX) Maxim Group analyst Naz Rahman maintained a Buy rating on Viking Therapeutics yesterday and set a price target of $10.00. The company's shares closed last Thursday at $4.03. According to TipRanks.
Viking Therapeutics, Inc. (VKTX)
Q3 2022 Earnings Conference Call
October 26, 2022 04:30 PM ET
Stephanie Diaz - Manager, Investor Relations
Brian Lian - President & Chief Executive Officer
Greg Zante - Chief Financial Officer
Conference Call Participants
Steve Seedhouse - Raymond James
Joon Lee - Truist
Andy Hsieh - William Blair
Thomas Smith - SVB Securities
Yale Jen - Laidlaw
Scott Henry - ROTH Capital
Justin Zelin - BTIG
Naz Rahman - Maxim Group
Welcome to the Viking Therapeutics' 2022 Third Quarter Financial Results Conference Call. At this time, all participan...
VKTX Price Returns